NCT02273700View on ClinicalTrials.gov

Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban

Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.

Trial Locations (1)

30029

CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT02273700 - Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention | Biotech Hunter | Biotech Hunter